Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY3844583
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
LY3844583 is a monoclonal antibody developed by Eli Lilly for the treatment of atopic dermatitis. It acts as an inhibitor of the glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), also known as TNFRSF18. The drug was designed to modulate immune responses by antagonizing GITR, a target involved in T-cell activation and regulation. Its development represented a novel approach to treating inflammatory skin diseases such as atopic dermatitis. Clinical trials were conducted to assess its safety and tolerability in both healthy participants and those with atopic dermatitis; however, development was discontinued after phase 1 due to lack of efficacy[1][2][3].
- Other names
- GITR antagonist antibodyGlucocorticoid-induced TNFR-related protein antagonist
02
Targets
TNFRSF18 (GITR)
Beyond the preview
Go deeper on LY3844583.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY3844583.